When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mainly used to make the site work as you expect it to. The information does not directly identify you but can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to learn more and change our default settings. However, blocking some types of cookies may impact your experience of the site. You can find more information, including a detailed cookie explanation, on our Cookie Policy.
QP-Prostate

Discover QP-Prostate®
Prostate cancer ranks as the second most prevalent cancer in men, posing a significant public health concern. While MRI scans are vital for early detection, the increased demand for scans has outpaced the growth of radiology experts. This has resulted in diagnostic delays and inconsistent interpretations, with only a minority of the medical community adhering to PI-RADS 2.1 guidelines.
Introducing QP-Prostate, an AI-powered solution designed to streamline radiologists’ workflows. By automatically evaluating image quality, segmenting the prostate gland, and identifying suspicious lesions*, QP-Prostate empowers radiologists to deliver quicker and more accurate assessments, ultimately enhancing patient care.
A suite of enhanced diagnostic capabilities
1. AI-based automated lesion detection*
Our AI algorithm, trained with pathology outcomes as ground truth, is designed to efficiently detect clinically significant prostate cancer lesions using biparametric inputs (T2w, DWI and ADC), with plans to outperform competitors in detection rate and speed. These AI algorithms are intended to elevate radiologists’ diagnostic accuracy with automated detection of biopsy-proven, clinically significant prostate cancer lesions.
2. Precision in segmentation
QP-Prostate’s AI algorithm, based on Convolutional Neural Networks (CNNs), automatically segments the prostate gland with market-leading performance (88% DSC1). It segments three key subregions (Peripheral, Transitional+Central zones, and Seminal Vesicles), incudes PI-RADS2.1 regions, and computes the prostate volume, facilitating PSA density calculations and fusion biopsy planning.
3. Quantitative diffusion and perfusion data
QP-Prostate automatically verifies MRI acquisition protocol according to PI-RADSv2.1 guidelines, ensuring that radiologists work with high-quality MRI examinations from the start.
QP-Prostate provides spatially registered, motion corrected, synthesized b-1400s/mm2 DWI and ADC map series, offering rich quantitative diffusion information. This dataset empowers radiologists to analyze potentially cancerous lesions with confidence. For mpMRI studies, perfusion analysis (Ktrans, Kep, Ve maps) are automatically generated.
4. Cloud to PACS integration
Ensure consistent and seamless incorporation of all outputs from QP-Prostate into your hospital’s PACS with no disruptions to radiologists’ workflow.
5. Structured radiology reports
QP-Prostate creates structured reports according to PI-RADSv2.1. The solution provides prostate volume and dimensions, and allows the radiologist to mark all relevant lesions and score them as per PI-RADSv2.1 guidelines.
The product will be enhanced with predictive capabilities in upcoming versions, which are currently undergoing clinical studies for imaging-based prediction of biochemical relapse. Preliminary results show that combining MRI with clinical data predicts a 10-year biochemical recurrence with an area under the curve (AUC) of 0.84 to 0.872.
Changing the narrative in prostate diagnostics
References
– Jimenez-Pastor A, et al. Eur Radiol. 2023;33(7):5087-5096.
– Sánchez Iglesias Á, et al. Cancers (Basel). 2023;15(16):4163.
*CAUTION-Investigational device. Limited by Federal law to investigational use.
Related articles
-
Philips teams with imaging biomarker specialist Quibim on AI-based imaging and reporting solutions for MR prostate exams
Read more
-
Advanced Imaging Biomarkers in Prostate Cancer – A Leap Towards Precision in Risk Stratification and BCR Prediction
Read more
-
Prostate Region-Wise Imaging Biomarker Profiles for Risk Stratification and Biochemical Recurrence Prediction
Read more